Member Info for FlyingHigher

Top up after the placing

Sells showing as buys, delayed sells. The usual explanation.

Sorry yes, you're right they will be supplying Apple with the device with Nano tech.

It's almost certainly Nanoco because all communications have aligned so far.

When AR Glasses really take off is another issue. It all sounds gimmicky for me, so the risk is it's not the big inflection point Nanoco holders have been hoping for.

Popeye62 as an objective investor I make up my mind based on the best information available.

The reason I said strong sell at 12p was because there was no new information on the market to suggest there was any likely development of the heart valve and cash was severely depleted. The information surrounding the pursuit of a partner is a game-changer, hence I changed to buy again.

However, it's now in freefall with unanswered questions about the funding of the overall business.

It makes sense that it will settle at previous support for this reason, unless there's a new announcement regarding the new partner and a favourable funding arrangement, which could also happen.

People often say I have agenda, I don't.

It's a fast-changing scenario and people need to keep up.

Long-term is a no-brainer strong buy for me, but this will go lower first.

STM are very likely to be supplying Apple with the dots from Nanoco. I have little doubt about that.

As for the share buy back.

The suggested terms were clear.

10p - 12p per share, which means a massive return for people who got in at these levels.

A not so massive return for long-term holders.

They definitely need funds. When companies pitch a placing, they have to do it at an attractive price.

Nobody is going to buy substantial quantities on a spike up to 45p.

They would look at the share price chart and be too nervous.

15p is a very attractive price to enter.

Of course it's possible that funding will be part of whatever deal they make for heart valve licensing.

This is too cheap, but it will most likely get a bit cheaper before it rises again in my opinion

Hi everyone, before the recent surge from 20p to 60p and back, I didn't invest due to inevitable funding requirements.

There maybe more to come down the line, but this gets us over the line for now.

I don't invest anymore, but enjoy a fantasy portfolio.

SED is a strong buy at this point. Ride it up again and sell out!

It looks like this is tumbling down to around 15p. Then there's the placing!

Fundamentalanalysis chipping in with fundamentally wrong analysis.

The heart valve project will not be funded via dilution.

The business can be and most likely will be.

A placing is extremely likely, but they might put the announcement in with the wider funding news and the market will go bananas anyway OR RUA will be taken over as I keep saying. This is also very likely in my opinion.

The share price is falling due to the obvious short-term risk of imminent funding.

It's not as straight-forward as saying wait for the placing then buy this time though because the funding could include a massive inflection point for the company. If you bought at 30p+ and the share price falls to 15p again, don't worry. It's not going to be a problem in a few years time. Look at the historic share price and see how it was 160p on a hint of where the company is now very close to.

Disappointing update, dilution imminent!

This will fall substantially from here, however the long-term picture is very promising.

Great post flava, other than a third-party JV or takeover, the time-scale for commercialization is three years.

That's what deters the quick buck traders.

What an incredibly stupid conversation on this forum. So sad.

Potentially you have to wait 3 years for the heart valve project to reach full potential.

However, the funding for the project hasn't been agreed and the BoD are saying it won't be dilution.

So go figure.

Next news will be funding related:

1) A placing to fund the rest of the business for the foreseeable

2) A JV agreement of some kind.

3) A takeover.

Probably 1 & 2 or 3.

You've been spiked for now, but look at the share price graph and coverage for this share.

It was considered cheap at 160p with lesser certainty.

It's a ridiculous share price. I don't have cash but if I did I'd put it in here!

Does anyone have any thoughts on what third-party funding options could look like?

The RNS mentions the BoD are not looking to fund the vascular project themselves, so in my view:

1) A takeover seems likely because of the ludicrously depressed shareprice.

2) RUA become an IP partner, a third-party progresses the project and pay RUA royalties for the duration.

3) I keep dilution as a risk anyway just to be open-minded.

The second option may sound disappointing, however the reality is the company does not have the clout to fully progress the massive opportunities itself. We have to accept that any deal will likely result in a lesser return because RUA's negotiating hand is so weak. Even so, a royalty agreement will provide millions for years to come and massively boost the share price from this low point.

Just flagging my post yesterday.

The logical thing here would be a takeover.

The potential value of the business is comfortably over 500p and the staggering discount makes a lesser bid possible.

A lesser bid would likely be at a substantial premium to today's share price.

We can speculate on that, but the clear reference point we have is the decline from 160p on news of 510k approval delays.

Strong buy - Target 160p

High Risk: Additional funding, however even with additional funding there is plenty of value. It will just put a dampener on expectations as high as 542p.

I think a takeover could come in at at way over £1 per share, but this is probably a silly thing to say.

Obvious point here. A takeover is surely likely or even inevitable at this point.

A company worth £5m wants to form a partnership with a third-party for a £6m project.

A big fish could come in now, but what price will they pay given the potential?

You don't usually see staggering premiums to the share price being offered, but given the discount on the current share price, I think this could be an exception.

We don't really need numbers for now. The company is losing hardly anything, with loads of cash in the bank.

The numbers would provide a short-term boost to the share price maybe, but we're not there yet.

We've been somewhere close to here before, where we've felt on the cusp of large-scale commercialization, but this feels very different. This actually sounds like it has substance.

The timescales are boring and I wouldn't blame people for running out of patience, but in 3 years time this could actually be a decent volume producer making tens of millions. That would make today's valuation look way too cheap.

It's all still way too unclear though.

If you want a very dull investment that might make multiples, but will take a long time to get there, this is a buy.

The risk is the Asian customer terminates the agreement and Nanoco are left with no clear prospects at all, but their cash and assets cover the share price. Sentiment may decide otherwise though.

This is far from exciting. It's really dull.

Small-scale orders won't make any difference. We've seen them so many times before over the past 10 years.